Ziv-aflibercept: binding to more than VEGF-A--does more matter?
Publication
, Journal Article
Clarke, JM; Hurwitz, HI
Published in: Nat Rev Clin Oncol
January 2013
The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. Thus, VEGF-directed agents might be useful throughout the continuum of care in mCRC, but biomarkers are needed to identify patients likely to benefit.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Clin Oncol
DOI
EISSN
1759-4782
Publication Date
January 2013
Volume
10
Issue
1
Start / End Page
10 / 11
Location
England
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Survival Rate
- Recombinant Fusion Proteins
- Receptors, Vascular Endothelial Growth Factor
- Prognosis
- Lung Neoplasms
- Humans
- Colorectal Neoplasms
- Clinical Trials, Phase III as Topic
- Carcinoma, Non-Small-Cell Lung
Citation
APA
Chicago
ICMJE
MLA
NLM
Clarke, J. M., & Hurwitz, H. I. (2013). Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nat Rev Clin Oncol, 10(1), 10–11. https://doi.org/10.1038/nrclinonc.2012.197
Clarke, Jeffrey M., and Herbert I. Hurwitz. “Ziv-aflibercept: binding to more than VEGF-A--does more matter?” Nat Rev Clin Oncol 10, no. 1 (January 2013): 10–11. https://doi.org/10.1038/nrclinonc.2012.197.
Clarke JM, Hurwitz HI. Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nat Rev Clin Oncol. 2013 Jan;10(1):10–1.
Clarke, Jeffrey M., and Herbert I. Hurwitz. “Ziv-aflibercept: binding to more than VEGF-A--does more matter?” Nat Rev Clin Oncol, vol. 10, no. 1, Jan. 2013, pp. 10–11. Pubmed, doi:10.1038/nrclinonc.2012.197.
Clarke JM, Hurwitz HI. Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nat Rev Clin Oncol. 2013 Jan;10(1):10–11.
Published In
Nat Rev Clin Oncol
DOI
EISSN
1759-4782
Publication Date
January 2013
Volume
10
Issue
1
Start / End Page
10 / 11
Location
England
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Survival Rate
- Recombinant Fusion Proteins
- Receptors, Vascular Endothelial Growth Factor
- Prognosis
- Lung Neoplasms
- Humans
- Colorectal Neoplasms
- Clinical Trials, Phase III as Topic
- Carcinoma, Non-Small-Cell Lung